FOXO4-DRI: Senolytic Peptide Research Profile

Overview

FOXO4-DRI is one of the most discussed compounds in cellular senescence research. It is a D-retro-inverso peptide designed to disrupt the protein–protein interaction between FOXO4 (a transcription factor) and p53 (the tumor-suppressor protein) inside senescent cells. The peptide is named for its origin sequence (from FOXO4) and its chemistry (DRI = D-amino acid retro-inverso, a modification that improves proteolytic stability while preserving the shape of the interaction surface).

Mechanism

Senescent cells stop dividing but persist in tissues, secreting pro-inflammatory signals collectively called the senescence-associated secretory phenotype (SASP). They are implicated in tissue dysfunction across aging and in post-chemotherapy contexts.

In senescent cells, nuclear FOXO4 binds and sequesters p53, blocking p53's pro-apoptotic activity. This is part of how senescent cells resist dying. FOXO4-DRI was designed as a competitive disruptor of this interaction — it binds FOXO4 in a way that releases p53, which then drives senescent-cell apoptosis. Non-senescent cells rely less on this specific sequestration and are correspondingly less affected.

Research Evidence

The defining study is Baar et al., Cell 2017, which reported that FOXO4-DRI administration improved outcomes across multiple endpoints in aged and chemotherapy-exposed mice — including fur density, fitness, kidney function markers, and mobility. The results were striking enough that FOXO4-DRI became a reference point for peptide senolytics generally.

Since then, additional preclinical work has extended the literature in mouse, rat, and cellular systems. However:

• Controlled human clinical data are minimal.
• Long-term safety in humans is unknown.
• Commercial senolytic development has generally moved toward small molecules (for example dasatinib + quercetin combinations, navitoclax-class compounds) rather than this specific peptide.

Why This Matters

Senescent-cell clearance is one of the most active areas in aging biology, tied directly to the cellular senescence hallmark. FOXO4-DRI matters because:

• It was an early proof-of-concept for peptide-based senolytics.
• It illustrates the protein–protein interaction disruption strategy — an increasingly important drug-design approach.
• It sits at the center of discussions about which senolytic modality (small molecule vs peptide) will reach clinical application first.

Realistic Status

FOXO4-DRI is not an approved therapy anywhere. It is not a clinical product. Marketing that positions it as an available anti-aging compound runs far ahead of the evidence. Responsible framing treats it as an experimental research peptide with mouse-level efficacy data and no established human profile.

See: Anti-aging and longevity peptides map for the broader Hallmarks-of-Aging framework in which senolytic research sits.

Storage

• Temperature: −20°C or below (lyophilized)
• Protect from light and moisture
• D-retro-inverso chemistry improves stability over the native peptide, but storage discipline still matters

This information is for research and educational purposes only. FOXO4-DRI is experimental and has not been approved for human use in any jurisdiction.